New combo therapy trial aims to boost red blood cells in blood cancer patients
NCT ID NCT07463820
Summary
This study tests whether adding other drugs to luspatercept helps patients with a lower-risk type of myelodysplastic syndrome (MDS) who have anemia. The goal is to improve red blood cell counts and reduce the need for blood transfusions. About 270 adults who haven't had prior MDS treatment will receive one of three drug combinations and be monitored for response and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.